JP2000507936A - アンモニウム化合物および/または尿素の新規用途 - Google Patents
アンモニウム化合物および/または尿素の新規用途Info
- Publication number
- JP2000507936A JP2000507936A JP9533393A JP53339397A JP2000507936A JP 2000507936 A JP2000507936 A JP 2000507936A JP 9533393 A JP9533393 A JP 9533393A JP 53339397 A JP53339397 A JP 53339397A JP 2000507936 A JP2000507936 A JP 2000507936A
- Authority
- JP
- Japan
- Prior art keywords
- urea
- sids
- ammonium
- milk
- toxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004202 carbamide Substances 0.000 title claims abstract description 63
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 150000003868 ammonium compounds Chemical class 0.000 title claims abstract description 29
- 208000034972 Sudden Infant Death Diseases 0.000 claims abstract description 46
- 206010042440 Sudden infant death syndrome Diseases 0.000 claims abstract description 46
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 25
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 25
- 235000008429 bread Nutrition 0.000 claims abstract description 21
- 235000013350 formula milk Nutrition 0.000 claims abstract description 19
- 239000008267 milk Substances 0.000 claims abstract description 19
- 210000004080 milk Anatomy 0.000 claims abstract description 19
- -1 ammonium ions Chemical class 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 235000013336 milk Nutrition 0.000 claims abstract description 17
- 108010046334 Urease Proteins 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims abstract description 4
- 230000000996 additive effect Effects 0.000 claims abstract description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 18
- 235000019270 ammonium chloride Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 7
- 150000003672 ureas Chemical class 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 210000003608 fece Anatomy 0.000 abstract description 2
- 235000013877 carbamide Nutrition 0.000 description 50
- 235000020256 human milk Nutrition 0.000 description 15
- 210000004251 human milk Anatomy 0.000 description 15
- 206010021143 Hypoxia Diseases 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000007954 hypoxia Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 201000004193 respiratory failure Diseases 0.000 description 5
- 208000005223 Alkalosis Diseases 0.000 description 4
- 206010027423 Metabolic alkalosis Diseases 0.000 description 4
- 230000002340 alkalosis Effects 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000015067 sauces Nutrition 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 206010011703 Cyanosis Diseases 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 206010021133 Hypoventilation Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229910001882 dioxygen Inorganic materials 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000005588 protonation Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 206010020591 Hypercapnia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000021216 bread soup Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000010235 enterohepatic circulation Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 208000000122 hyperventilation Diseases 0.000 description 2
- 230000000870 hyperventilation Effects 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000006443 lactic acidosis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 230000006506 pH homeostasis Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S297/00—Chairs and seats
- Y10S297/08—Inflatable bellows
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 人工栄養乳またはパンがゆへの添加物としての、または乳児突然死症候群 (SIDS)の予防用医薬組成物を製造するための生理的に無毒性のアンモニウ ム化合物および/または尿素の使用。 2. アンモニウム化合物および尿素がそれぞれ、適当であれば、0.2〜0. 6mmol/l、好ましくは約0.5mmol/lの濃度で、および1〜5mm ol/l、好ましくは約2mmol/lの濃度で、生後1か月の間の乳児に投与 するために用意され、投与することが意図されている人工栄養乳に添加される請 求項1記載の使用。 3. アンモニウム化合物および尿素がそれぞれ、適当であれば、0.1〜5m mol/l、好ましくは0.5〜2mmol/lの濃度で、および1〜10mm ol/l、好ましくは4〜6mmol/lの濃度で、生後2〜7か月の間の子供 に投与するために用意され、投与することが意図されている人工栄養乳に添加さ れる請求項1記載の使用。 4. 慣用の成分に加えて、生理的に無毒性のアンモニウム化合物および/また は尿素を生理的に無毒性で且つSIDSの予防に有効な濃度で含有することを特 徴とする人工栄養乳またはパンがゆ。 5. 粉末の形態である請求項4記載の人工栄養乳またはパンがゆ。 6. アンモニウム化合物が塩化アンモニウムである請求項4記載の人工栄養乳 またはパンがゆ。 7. 生理的に無毒性のアンモニウム化合物および/または尿素が生理的に無毒 性で且つSIDSの予防に有効な濃度で添加されている人工栄養乳またはパンが ゆを、乳児に投与することからなる、SIDSの予防方法。 8. 生理的に無毒性のアンモニウム化合物および/または尿素を生理的に無毒 性で且つSIDSの予防に有効な濃度で含有する医薬組成物を、乳児に投与する ことからなる、SIDSの予防方法。 9. 適切に選択および/または修飾された非病原性のウレアーゼ産生細菌を乳 児の胃腸管に投与することからなる、SIDSの予防方法。 10. 乳児の糞便を、SIDSの危険を示す、尿素、ウレアーゼ活性および/ またはアンモニウムイオンの存在、完全な尿素の存在、ウレアーゼ活性の欠如ま たは異常低活性、およびアンモニウムイオンについてそれぞれ分析することから なる、乳児におけるSIDSの危険を診断する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9601057-4 | 1996-03-20 | ||
SE9601057A SE507696C2 (sv) | 1996-03-20 | 1996-03-20 | Användning av en fysiologisk ofarlig ammoniumförening och/ eller urea för profylax av plötslig spädbarnsdöd samt sätt att diagnostisera risk för plötslig spädbarnsdöd |
PCT/SE1997/000361 WO1997034590A1 (en) | 1996-03-20 | 1997-03-04 | New use of ammonium compounds and/or urea |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000507936A true JP2000507936A (ja) | 2000-06-27 |
JP2000507936A5 JP2000507936A5 (ja) | 2005-10-06 |
Family
ID=20401857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9533393A Pending JP2000507936A (ja) | 1996-03-20 | 1997-03-04 | アンモニウム化合物および/または尿素の新規用途 |
Country Status (14)
Country | Link |
---|---|
US (2) | US6333055B1 (ja) |
EP (1) | EP0888112B1 (ja) |
JP (1) | JP2000507936A (ja) |
AT (1) | ATE219935T1 (ja) |
AU (1) | AU722642B2 (ja) |
CA (1) | CA2249704A1 (ja) |
DE (1) | DE69713746T2 (ja) |
DK (1) | DK0888112T3 (ja) |
ES (1) | ES2176721T3 (ja) |
NO (1) | NO984194L (ja) |
NZ (1) | NZ331185A (ja) |
PT (1) | PT888112E (ja) |
SE (1) | SE507696C2 (ja) |
WO (1) | WO1997034590A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572528B1 (en) | 2012-08-06 | 2017-02-21 | Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center | Monitor for SIDS research and prevention |
EP3646739A1 (en) | 2018-11-01 | 2020-05-06 | N.V. Nutricia | Nutritional composition comprising urea and non-digestible oligosaccharides |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4668772A (en) * | 1984-11-27 | 1987-05-26 | Nestec S.A. | Methods for controlling the viscosity of protein hydrolysates |
CA1297721C (en) * | 1987-01-26 | 1992-03-24 | Shalan A. Al-Mashiki | PROCESS FOR LOWERING THE CONCENTRATION OF .beta.-LACTOGLOBULIN IN CHEESE WHEY |
US5312839A (en) | 1991-03-05 | 1994-05-17 | Regents Of The University Of California | Compounds and method for protection of cells and tissues from irreversible injury due to lactic acidosis |
US5169666A (en) * | 1991-11-14 | 1992-12-08 | The United States Of America As Represented By The Secretary Of Agriculture | Preparation of simulated human milk protein by low temperature microfiltration |
AUPM864894A0 (en) | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
-
1996
- 1996-03-20 SE SE9601057A patent/SE507696C2/sv not_active IP Right Cessation
-
1997
- 1997-03-04 JP JP9533393A patent/JP2000507936A/ja active Pending
- 1997-03-04 US US09/142,145 patent/US6333055B1/en not_active Expired - Fee Related
- 1997-03-04 ES ES97914690T patent/ES2176721T3/es not_active Expired - Lifetime
- 1997-03-04 NZ NZ331185A patent/NZ331185A/xx unknown
- 1997-03-04 PT PT97914690T patent/PT888112E/pt unknown
- 1997-03-04 AT AT97914690T patent/ATE219935T1/de not_active IP Right Cessation
- 1997-03-04 EP EP97914690A patent/EP0888112B1/en not_active Expired - Lifetime
- 1997-03-04 DE DE69713746T patent/DE69713746T2/de not_active Expired - Fee Related
- 1997-03-04 WO PCT/SE1997/000361 patent/WO1997034590A1/en active IP Right Grant
- 1997-03-04 CA CA002249704A patent/CA2249704A1/en not_active Abandoned
- 1997-03-04 AU AU21840/97A patent/AU722642B2/en not_active Ceased
- 1997-03-04 DK DK97914690T patent/DK0888112T3/da active
-
1998
- 1998-09-11 NO NO984194A patent/NO984194L/no not_active Application Discontinuation
-
2001
- 2001-11-15 US US09/987,558 patent/US20030021856A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2176721T3 (es) | 2002-12-01 |
US6333055B1 (en) | 2001-12-25 |
ATE219935T1 (de) | 2002-07-15 |
DE69713746D1 (de) | 2002-08-08 |
CA2249704A1 (en) | 1997-09-25 |
PT888112E (pt) | 2002-11-29 |
NZ331185A (en) | 2000-05-26 |
NO984194D0 (no) | 1998-09-11 |
EP0888112A1 (en) | 1999-01-07 |
AU2184097A (en) | 1997-10-10 |
DE69713746T2 (de) | 2002-11-21 |
DK0888112T3 (da) | 2002-10-21 |
SE9601057D0 (sv) | 1996-03-20 |
SE9601057L (sv) | 1997-09-21 |
EP0888112B1 (en) | 2002-07-03 |
US20030021856A1 (en) | 2003-01-30 |
SE507696C2 (sv) | 1998-07-06 |
WO1997034590A1 (en) | 1997-09-25 |
NO984194L (no) | 1998-09-11 |
AU722642B2 (en) | 2000-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3224767B2 (ja) | 経口用亜鉛組成物 | |
TWI359021B (en) | Nutritional composition for controlling blood suga | |
KR101075816B1 (ko) | 종합 경장 영양 조성물 | |
JPH0662422B2 (ja) | 核酸成分組成物 | |
US5340603A (en) | Nutritional product for human infants having chronic lung disease | |
JP2008247748A (ja) | 透析患者用栄養組成物 | |
Schanler et al. | Parenteral nutrition in premature infants | |
ES2814951T3 (es) | Compuestos y sus efectos sobre el control del apetito y la sensibilidad a la insulina | |
US20070178172A1 (en) | Composition for reducing blood lipids | |
CN102273581A (zh) | 一种高甜度复配甜味剂 | |
JP2000507936A (ja) | アンモニウム化合物および/または尿素の新規用途 | |
CN115918914A (zh) | 一种含复合蛋白的口服营养补充剂,制备及应用 | |
Wassner et al. | Diminished linear growth associated with chronic salt depletion | |
JPH0328403B2 (ja) | ||
Principi et al. | The role of zinc in total parenteral nutrition | |
PAIRENT et al. | The treatment of pancreatic exocrine insufficiency: III. The effects of pancreatic ductal ligation and oral pancreatic enzyme supplements on fecal lipid excretion in the dog | |
WO2010119804A1 (ja) | 抗精神疲労剤 | |
JP3556757B2 (ja) | 吸収促進性糖類組成物 | |
JP4953642B2 (ja) | 経口経腸栄養剤の投与前処置液 | |
EP4137206A1 (en) | Agent for improving quality of sleep | |
JP2009523755A (ja) | 治療食品の製造へのヒト又は家畜使用用ポリアミン欠乏食品組成物の新規使用 | |
Wilmore et al. | Feeding the patient | |
Valentine et al. | Nutritional support in children | |
Davies | Problems of the newborn. Feeding. | |
JPH02191227A (ja) | 高カロリー輸液基本液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080519 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080715 |